Skip to main content
SpringerLink
Log in

Neue Analyse der CRYSTAL-Studie

mCRC-Therapie mit Cetuximab

  • infopharm
  • Published:
Info Onkologie Aims and scope

Eine retrospektive Analyse der Phase-III-Studie CRYSTAL bestätigt die Bedeutung der erweiterten Mutationstestung vor dem Therapiestart mit Cetuximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Meet the Expert „CRYSTAL RAS wt Analysis: Impact on clinic and practise“ anlässlich der ASCO-Jahrestagung 2014, Chicago, IL/USA, 30. Mai 2014; Veranstalter: Merck Serono

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Silke Wedekind

Authors
  1. Silke Wedekind
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wedekind, S. Neue Analyse der CRYSTAL-Studie. Info Onkol. 17, 52 (2014). https://doi.org/10.1007/s15004-014-0906-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-014-0906-y

Search

Navigation